Sodium Zirconium Cyclosilicate
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Sodium Zirconium Cyclosilicate
- Sodium Zirconium Cyclosilicate: From an Unspecified Original Indication to Breast Fibrocystic Disease
Sodium Zirconium Cyclosilicate: From an Unspecified Original Indication to Breast Fibrocystic Disease
One-Sentence Summary
Sodium zirconium cyclosilicate is a non-absorbed potassium binder that acts in the gastrointestinal tract. The Singapore registration data compiled for this report do not list an approved indication for it. The TxGNN model predicts it may be effective for breast fibrocystic disease (score 93.4%), but 0 clinical trials and 0 publications support this prediction, so it is a model-based prediction only.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not stated in the Singapore registration data |
| Predicted New Indication | Breast fibrocystic disease |
| TxGNN Prediction Score | 93.41% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 2 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the compiled data. Based on general pharmacology, sodium zirconium cyclosilicate is a non-absorbed inorganic cation exchanger. It selectively traps potassium (and some ammonium) in the gastrointestinal tract. It is not absorbed into the body.
No plausible mechanistic link to fibrocystic breast disease was identified. Nothing in the drug's known pharmacology relates to the hormonal or epithelial changes behind fibrocystic breast conditions. The high score (0.934) most likely reflects proximity in the knowledge graph, not biological reasoning.
The other top predictions are also unsupported. Nine further predictions (ranks 2-10) are all L5 with no trials or literature. Eight are benign breast or lactation conditions, scoring 0.905-0.923. They share nearly identical scores, which suggests a common graph neighbourhood rather than independent evidence. Two are inherited clotting disorders (heparin cofactor 2 deficiency and antithrombin deficiency type 2), with no known link to this drug.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN15961P | LOKELMA POWDER FOR ORAL SUSPENSION 5G | Powder, for suspension | Not stated in the registration data |
| SIN15962P | LOKELMA POWDER FOR ORAL SUSPENSION 10G | Powder, for suspension | Not stated in the registration data |
Safety Considerations
- Drug Interactions: 16 interactions were found, all rated Moderate. The drugs involved are:
- HIV antivirals: atazanavir, rilpivirine, ritonavir, saquinavir, nelfinavir, indinavir, raltegravir
- Azole antifungals: itraconazole, posaconazole, ketoconazole
- Cancer drugs: dasatinib, nilotinib, erlotinib
- Others: atorvastatin, ledipasvir, furosemide
Please refer to the package insert for warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests only on a graph-based score. There are no clinical trials or publications, and no plausible mechanism connects a non-absorbed gastrointestinal potassium binder to breast tissue. The other top predictions share the same weakness.
To proceed, the following is needed:
- Mechanism of action data, to test whether any biological link exists
- Package insert warnings and contraindications (from the HSA website)
- The approved indication text for the Singapore licences
- Any preclinical or clinical evidence for the predicted indication. Without it, the prediction should not advance.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.